Healthcare [ 12/13 ] | Medical Devices [ 109/164 ]
NASDAQ | Common Stock
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide.
The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions.
In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com.
Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 25, 24 | 0.66 Decreased by -24.14% | 0.69 Decreased by -4.35% |
| Feb 27, 24 | 1.06 Decreased by -19.70% | 0.88 Increased by +20.45% |
| Nov 7, 23 | 0.63 Decreased by -37.00% | 0.59 Increased by +6.78% |
| Aug 8, 23 | 0.62 Decreased by -54.07% | 0.56 Increased by +10.71% |
| May 9, 23 | 0.87 Decreased by -6.45% | 0.83 Increased by +4.82% |
| Feb 28, 23 | 1.32 Increased by +9.09% | 1.18 Increased by +11.86% |
| Nov 8, 22 | 1.00 Increased by +6.38% | 0.92 Increased by +8.70% |
| Aug 9, 22 | 1.35 Increased by +43.62% | 1.20 Increased by +12.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 492.80 M Decreased by -12.78% | 18.90 M Decreased by -11.27% | Increased by +3.84% Increased by +1.73% |
| Dec 31, 23 | 548.90 M Decreased by -11.04% | 33.90 M Decreased by -17.11% | Increased by +6.18% Decreased by -6.83% |
| Sep 30, 23 | 478.90 M Decreased by -12.82% | 10.60 M Decreased by -72.03% | Increased by +2.21% Decreased by -67.92% |
| Jun 30, 23 | 455.30 M Decreased by -19.46% | 15.70 M Decreased by -13.26% | Increased by +3.45% Increased by +7.70% |
| Mar 31, 23 | 565.00 M Increased by +85.71% | 21.30 M Decreased by -54.29% | Increased by +3.77% Decreased by -75.39% |
| Dec 31, 22 | 617.00 M Increased by +88.35% | 40.90 M Decreased by -40.08% | Increased by +6.63% Decreased by -68.19% |
| Sep 30, 22 | 549.30 M Increased by +78.68% | 37.90 M Decreased by -34.43% | Increased by +6.90% Decreased by -63.30% |
| Jun 30, 22 | 565.30 M Increased by +85.27% | 18.10 M Decreased by -63.94% | Increased by +3.20% Decreased by -80.54% |